News | January 27, 2025
Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
Q3 FY25 revenue up 24% to Rs 3,230 crore
Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
PAT after MI is Rs. 41 crore which is 162% increase
EBITDA margins expand to 31.3%
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Subscribe To Our Newsletter & Stay Updated
